Gaxos.AI Reports 1,353% Revenue Growth to $2.46 Million in Q2 2026

Gaxos.AI Inc. reported significant financial growth in its latest quarterly filing, with revenues reaching $2.46 million for the three months ended June 30, 2026, compared to just $171,000 during the same period in 2025. This marks an increase of approximately 1,353%, driven primarily by revenue from its RNK Health subsidiary, which generated $1.74 million in non-clinical administrative services. For the first half of 2026, total revenues amounted to $4.27 million, a substantial rise from $195,000 in the prior year. Despite this revenue growth, the company reported a net loss of $22,233 for the second quarter, a significant improvement from a loss of $824,572 in the same quarter of 2025.

The company’s operating expenses also saw a dramatic increase, totaling $4.32 million for the second quarter of 2026, up from $1.15 million in the previous year, reflecting a 275% rise. This increase was largely attributed to heightened advertising and marketing expenditures, which surged to $3.14 million from $431,000, as Gaxos.AI ramped up efforts to promote its services and products. Research and development costs also rose, reflecting ongoing investments in the development of its AI applications. The overall loss from operations for the second quarter was $1.86 million, compared to a loss of $982,694 in the prior year.

In terms of strategic developments, Gaxos.AI completed the sale of its gaming assets to Game Foundry AI on June 18, 2026, for an estimated consideration of $1.76 million, which included the issuance of 2.2 million shares of the buyer's common stock. This divestiture aligns with the company's focus on expanding its AI-driven health and wellness solutions, as well as its Gaxos Labs product studio, which has launched several AI applications in recent years. The company also reported a significant increase in its employee headcount, reflecting its growth strategy and expansion into new markets.

As of June 30, 2026, Gaxos.AI had total assets of $17.46 million, up from $13.42 million at the end of 2025. The company’s cash position improved to $1.09 million, alongside short-term investments of $10.35 million. The increase in total assets was primarily driven by the proceeds from the sale of common stock under an At The Market Offering Agreement, which generated approximately $6.32 million in net proceeds during the first half of 2026. The company reported working capital of $10.77 million, indicating a solid liquidity position to support its ongoing operations and growth initiatives.

Looking ahead, Gaxos.AI anticipates continued operating losses as it invests in research and development and marketing to drive growth. The company believes its existing cash and working capital will be sufficient to meet its operational needs for at least the next twelve months. Gaxos.AI remains focused on leveraging its AI technologies to enhance user experiences across various sectors, including health and wellness, while also exploring new revenue opportunities through its expanding product offerings.